Author:
Maroto Pablo,Solsona Eduardo,Gallardo Enrique,Mellado Begoña,Morote Juan,Arranz José Ángel,Gómez-Veiga Francisco,Unda Miguel,Climent Miguel Ángel,Alcaraz Antonio
Reference88 articles.
1. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies;Al Nakouzi;Eur. Urol.,2015
2. Duration of response to androgen-deprivation therapy and efficacy of secondary hormone therapy, docetaxel, and cabazitaxel in metastatic castration-resistant prostate cancer;Angelergues;J. Clin. Oncol.,2014
3. Anon, 2011. Taxotere® (Docetaxel). Summary of product characteristics. Available from: [accessed 22.07.14.].
4. Anon, 2012. Guidelines on prostate cancer. European Association of Urology. Available from: [accessed 22.07.14.].
5. Anon, 2013a. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). Available from: [accessed 22.07.14.].
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献